Английская Википедия:Filorexant

Материал из Онлайн справочника
Версия от 17:02, 7 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Drugbox | IUPAC_name = [(2''R'',5''R'')-5-{[(5-Fluoro-2-pyridinyl)oxy]methyl}-2-methyl-1-piperidinyl][5-methyl-2-(2-pyrimidinyl)phenyl]methanone | image = Filorexant.svg | width = 250 | CAS_number_Ref = {{cascite|correct|CAS}} | CAS_number = 1088991-73-4 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = E6BTT8VA5Z | ATC_prefix = None | ATC_suffix =...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Filorexant (Шаблон:Abbrlink, Шаблон:Abbrlink; developmental code name MK-6096) is an orexin antagonist which was under development by Merck for the treatment of insomnia, depression, diabetic neuropathy, and migraine.[1][2] It is a dual antagonist of the orexin OX1 and OX2 receptors.[3][4] It has a relatively short elimination half-life of 3 to 6Шаблон:Nbsphours.[5] However, it dissociates slowly from the orexin receptors and may thereby have a longer duration.[6] Possibly in relation to this, filorexant shows next-day somnolence similarly to suvorexant.[6] In phase 2 clinical trials, filorexant was found to be effective in the treatment of insomnia,[7] but was not effective in the treatment of major depressive disorder,[8][9][10] painful diabetic neuropathy,[11][12] or migraine.[13] Шаблон:As of, filorexant was no longer listed on Merck's online development pipeline and hence development of the drug appears to have been discontinued.[14][5][1] Development of filorexant may have been discontinued due to lack of differentiation from suvorexant (which was also developed by Merck).[6]

See also

References

Шаблон:Reflist

External links

Шаблон:Orexin receptor modulators

Шаблон:Nervous-system-drug-stub